Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromes.
Tamburini
J
J
Department of haematology, Hôpital Cochin, France. tamburini@cochin.inserm.fr
Elie
C
C
Park
S
S
Beyne-Rauzy
O
O
Gardembas
M
M
Berthou
C
C
Mahe
B
B
Sanhes
L
L
Stamatoullas
A
A
Vey
N
N
Aouba
A
A
Slama
B
B
Quesnel
B
B
Vekhoff
A
A
Sotto
J J
JJ
Vassilief
D
D
Al-Nawakil
C
C
Fenaux
P
P
Dreyfus
F
F
Bouscary
D
D
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D013792:Thalidomide / Q000008:administration & dosage* / Q000009:adverse effects*
D020533:Angiogenesis Inhibitors; D013792:Thalidomide